

CHINA MEDICAL (INTERNATIONAL) GROUP LIMITED

(Incorporated in the Republic of Singapore)
(Company Registration No. 200505118M)

PROPOSED RENOUNCEABLE AND NON-UNDERWRITTEN RIGHTS CUM WARRANTS ISSUE – RESULTS OF THE RIGHTS CUM WARRANTS ISSUE

Unless otherwise defined, all capitalised terms used in this announcement shall bear the same meanings as ascribed to them in the Company's offer information statement dated 3 October 2017 in relation to the proposed renounceable and non-underwritten rights cum warrants issue of up to 10,107,788,721 new ordinary shares in the capital of the Company with up to 10,107,788,721 free detachable warrants (the "Offer Information Statement"). Any reference to the time of day and date herein shall be a reference to Singapore time and date, respectively.

1. RESULTS OF THE RIGHTS CUM WARRANTS ISSUE

Level of Subscription

- 1.1. The Board of Directors ("Directors") of China Medical (International) Group Limited (the "Company", and together with its subsidiaries, the "Group") wishes to announce that, based on the total issued share capital of the Company comprising 3,199,133,315 Shares as at the Books Closure Date, 9,597,399,945 Rights Shares with 9,597,399,945 Warrants were available for subscription under the Rights cum Warrants Issue and as at the Closing Date, valid acceptances and Excess Applications for a total of 5,601,440,009 Rights Shares with Warrants were received. This represents approximately 58.36% of the total number of Rights Shares with Warrants available for subscription under the Rights cum Warrants Issue.
- 1.2. Details of the valid acceptances and Excess Applications for the Rights Shares with Warrants received are as follows:
 - 1.2.1. valid acceptances were received for a total of 4,118,366,366 Rights Shares with Warrants, representing approximately 42.91% of the total number of Rights Shares with Warrants available for subscription under the Rights cum Warrants Issue; and
 - 1.2.2. Excess Applications were received for a total of 1,483,073,643 Rights Shares with Warrants, representing approximately 15.45% of the total number of Rights Shares with Warrants available for subscription under the Rights cum Warrants Issue.

Allocation of Rights Shares with Warrants for Excess Applications

- 1.3. A total of 5,479,033,579 Rights Shares with Warrants were not taken up by Entitled Shareholders and/or their renounees pursuant to the Rights cum Warrants Issue. 1,483,073,643 of these Rights Shares with Warrants not taken up were allocated to satisfy all valid Excess Applications for the Rights Shares with Warrants.

Allotment of Rights Shares with Warrants

- 1.4. In the case of Entitled Depositors, their renounees and Purchasers with valid acceptances of Rights Shares with Warrants and successful applications for excess Rights Shares with Warrants, share certificate(s) and warrant certificate(s) representing such number of Rights Shares and Warrants will be sent to CDP within 10 Market Days after the Closing Date and CDP will thereafter credit such number of Rights Shares and Warrants to their relevant Securities Accounts. CDP will then send to the relevant subscribers by ordinary post, at their own risk, a notification letter stating the number of Rights Shares and Warrants credited to their Securities Accounts.
- 1.5. As at the Books Closure Date, there are no Entitled Scripholders.

“Nil-paid” Rights in respect of Foreign Shareholders

- 1.6. None of the “nil-paid” Rights Shares with Warrants which would otherwise have been provisionally allotted to Foreign Shareholders were sold on the SGX-ST. Accordingly, there are no proceeds to be distributed to Foreign Shareholders.

2. INVALID/UNSUCCESSFUL ACCEPTANCES AND EXCESS APPLICATIONS

- 2.1. Where any acceptance of the Rights Shares with Warrants and/or application for excess Rights Shares with Warrants is invalid or unsuccessful in full or in part, the amount paid on acceptance and/or application, or the surplus application monies, as the case may be, will be returned or refunded to such applicants by CDP on behalf of the Company without interest or any share of revenue or other benefit arising therefrom within 14 days after the Closing Date by any one or a combination of the following:
 - 2.1.1. where the acceptance and/or application had been made through an Electronic Application through an ATM, by crediting the relevant applicant’s bank account with the relevant Participating Bank at the applicant’s own risk, the receipt by such bank being a good discharge to the Company and CDP of their obligations, if any, thereunder;
 - 2.1.2. where the acceptance and/or application had been made through the Share Registrar, by means of a crossed cheque drawn in Singapore currency on a bank in Singapore and sent by ordinary post at the relevant applicant’s own risk to the relevant applicant’s mailing address as recorded with the Share Registrar; and/or
 - 2.1.3. where the acceptance and/or application had been made through CDP, by means of a crossed cheque in Singapore currency drawn on a bank in Singapore and sent by ordinary post at the relevant applicant’s own risk to the relevant applicant’s mailing address as maintained with CDP or in such other manner as they may have agreed with CDP for the payment of any cash distributions, as the case may be.

3. ISSUE AND LISTING OF THE RIGHTS SHARES, THE WARRANTS AND THE ADDITIONAL OUTSTANDING WARRANTS

- 3.1. The Company is pleased to announce that 5,601,440,009 Rights Shares and 5,601,440,009 Warrants have been allotted and issued by the Company pursuant to the Rights cum Warrants Issue on 30 October 2017.

- 3.2. The Rights Shares will be listed and quoted on Catalist on 31 October 2017, and the trading of the Rights Shares on Catalist under the book-entry (scripless) settlement system will commence with effect from 9.00 a.m. on the same date.
- 3.3. The Warrants will be listed and quoted on Catalist on 1 November 2017, and the trading of the Warrants on Catalist under the book-entry (scripless) settlement system will commence with effect from 9.00 a.m. on the same date.
- 3.4. Following the allotment and issue of 5,601,440,009 Rights Shares, the number of Shares (excluding treasury shares) has increased from 3,199,133,315 Shares to 8,800,573,324 Shares.
- 3.5. The Additional Outstanding Warrants will be issued on 31 October 2017 on the basis of 1.6047 Additional Outstanding Warrants to be issued for every one (1) Outstanding Warrant held by each Warranholder. The adjustment to the number of Outstanding Warrants held by each Warranholder will be rounded down to the nearest whole Outstanding Warrant, fractional entitlements to be disregarded.
- 3.6. The Additional Outstanding Warrants will be listed and quoted on the Official List of the SGX-ST with effect from 9.00 a.m. on 1 November 2017. A further announcement on the above will be made by the Company in due course.
- 3.7. The listing and quotation notice granted by the SGX-ST for the admission to Catalist and the dealing in, listing of and quotation for, the Rights Shares, the Warrants and the New Shares, the Additional Outstanding Warrants and Additional New Shares is not an indication of the merits of the Rights cum Warrants Issue, the Rights Shares, the Warrants, the New Shares, the Additional Outstanding Warrants, the Additional New Shares, the Company, its subsidiaries and their securities.

4. NET PROCEEDS FROM THE RIGHTS CUM WARRANTS ISSUE

- 4.1. The Company has raised net proceeds of approximately S\$5.5 million (after deducting estimated expenses of approximately S\$0.12 million) from the Rights cum Warrants Issue (“**Net Proceeds**”).
- 4.2. As the Net Proceeds are less than the amounts set out for illustrative purposes in the Offer Information Statement, the Board will assess the allocation of the Net Proceeds for the principal intended uses mentioned in the Offer Information Statement (i.e. repayment of loans and/or debts; business expansion; and working capital) and will make the appropriate announcements in due course on the manner of use of the Net Proceeds.
- 4.3. Pending the deployment of the Net Proceeds, the Net Proceeds may be placed as deposits with financial institutions or invested in short-term money market or debt instruments or for any other purposes on a short-term basis as the Directors may, in their absolute discretion, deem fit in the interest of the Group.

By Order of the Board
30 October 2017

*This announcement has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “**Sponsor**”) for compliance with the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.*

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Lance Tan, Director, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).